BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BioCryst Pharmaceuticals Inc.

In a report released today, Laura Chico from Wedbush maintained a Buy rating on BioCryst, with a price target of $21.00. Chico covers the Healthcar...

BioCryst (BCRX) Receives a Buy from Wedbush

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on BioCryst, with a price target of $15.00. The company’s s...

RBC Capital Remains a Buy on BioCryst (BCRX)

In a report released today, Gena Wang from Barclays maintained a Hold rating on BioCryst, with a price target of $9.00. The company’s shares closed...

Barclays Sticks to Their Hold Rating for BioCryst (BCRX)

In a report released today, Serge Belanger from Needham maintained a Buy rating on BioCryst, with a price target of $18.00. The company’s shares cl...

BioCryst (BCRX) Gets a Buy from Needham

In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on BioCryst, with a price target of $30.00. The company’s shares opened ...

Current Quarter	$0.04	Next Quarter	$0.13
Current Year	$0.19	Next Year	$0.35
QoQ Growth	+225.0%	YoY Growth	+84.2%
3Y EPS CAGR	+25.3%	Target Price	$19.73
Consensus	Buy	Upside	+183.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BCRX	$6.97	-0.85%	3.91M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BCRX	$6.97	-0.9%	3.91M
3
4
5
6

BCRX

BCRX

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get BioCryst Pharmaceuticals Inc. Data in Excel

Get BioCryst Pharmaceuticals Inc. Data in Excel